Stubborn US inflation has kept interest rate risks in focus, which puts a premium on businesses that can grow through higher costs rather than just endure them. Australian fast growers where insiders own meaningful stakes offer exactly that angle, because management feels the impact of every swing alongside you. This article highlights three such stocks from our high growth, high insider ownership list so you can decide which, if any, deserve a closer look.
The three stocks highlighted here offer a compelling starting point if you want exposure to fast growing businesses where insiders have real skin in the game. However, if you want the names that matter most, these 27 high growth high conviction stocks are the strongest companies we’ve found.
Overview: PDI Gold is a West African gold producer focused on the Kiniéro Gold Mine in Guinea, which drives its growth profile.
Operations: PDI Gold generates about $156 million from Kiniéro and $47 million from Nampala, with Kiniéro contributing the bulk of revenue.
Market Cap: A$4.3 billion
PDI Gold sits neatly in this screener because Kiniéro is not just a development story but an operating mine that already underpins growth, while high insider ownership helps align capital allocation with that production ramp.
“Although Kiniero is ramping strongly with low reported all in sustaining costs and high throughput, the reliance on oxide ore for the next few years means a later shift to harder material could lift unit costs and pressure margins once the current “oxide holiday” ends. This would affect future net margins.”
What really matters for investors is how one future shift in the production mix influences the profit pool Kiniéro can sustain over time.
To see how that production mix could reshape the whole Kiniéro story, read the full narrative for PDI Gold which explains how management plans to support improving returns.
Overview: Telix Pharmaceuticals develops and commercialises precision radiopharmaceutical imaging agents and cancer therapies, with its prostate-focused TLX591 pipeline anchoring its high-growth, insider-backed thesis.
Operations: Telix generates about $705 million from Precision Medicine and $277 million from Manufacturing Solutions, largely tied to US$872 million of sales in the United States.
Market Cap: A$5.3 billion
Telix Pharmaceuticals matters in this fast growing, high insider ownership theme because its cancer radiopharmaceutical toolkit can scale if late-stage programs move from promising data to wider clinical use.
“Their primary revenue generating imaging agents: ‘Illuccix’ and ‘Gozellix’, are utilised in 23+ countries worldwide, including key markets such as the U.S, Europe, China and Japan, with revenue figures of $803.8m (USD) in the 2025 Financial Year (within their already upgraded guidance range) provided for FY25, a cash balance of $141.9m (USD), and the potential growth of Gozellix as its launch into the U.S expands.”
What really moves the Telix Pharmaceuticals story from here is how one future inflection in its late-stage cancer pipeline filters through to margins.
That is where the real hinge sits, and the full narrative for Telix Pharmaceuticals shows how Telix Pharmaceuticals could see margins decouple from headline sales as the pipeline matures.
Overview: Codan develops radio communications systems and metal detection equipment, with its DTC and Zetron units geared to high-demand, mission-critical networks.
Operations: Codan generates about A$506 million from Communications and A$362 million from Metal Detection, with other revenue of roughly A$7 million.
Market Cap: A$11.4 billion
Codan is relevant to this fast growth, high insider ownership theme because its communications arm is tightly connected to rising demand for resilient, mission-critical radio networks in defense, public safety, utilities, and drone systems.
“Heightened geopolitical tensions, increased defense spending, and the need for resilient communications infrastructure, especially in light of remilitarization and growing demand for unmanned systems, are expanding Codan’s customer base and forward order book in defense and public safety, driving both near-term and long-term revenue growth.”
The key variable is how changes in long-term unmanned systems demand ultimately affect Codan’s pricing power and margins.
If that pricing power shift is what you care about, the full narrative for Codan shows how Codan’s order book, margins and risk profile could be quietly accelerating.
Seeking Fresh Alternatives Before They Fly
Markets move fast and fresh opportunities do not stay quiet for long. Spot breakouts, catch momentum early, and avoid getting caught chasing dropping stories after the crowd arrives. Act now.
-
Target rock-solid balance sheets before they gain broad attention by running the list of solid balance sheet and fundamentals (12 results). This keeps financially resilient contenders in clear view while it still matters.
-
Ride potential gold momentum earlier in the cycle by scanning the 36 elite gold producer stocks, where elite producers are filtered for stronger fundamentals that may still be under the radar.
-
Position ahead of the next automation wave by tracking the 91 robotics and automation stocks, curated for robotics and automation leaders that appear to be building real traction before headlines catch up.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

